Clinical Pharmacology of Platelet, Monocyte, and Vascular Cyclooxygenase Inhibition by Naproxen and Low-Dose Aspirin in Healthy Subjects

Circulation

Volumn 109, Issue 12, 2004, Pages 1468-1471

  Capone, Marta L ^a   Tacconelli, Stefania ^a   Sciulli, Maria G ^a   Grana, Marilena ^a   Ricciotti, Emanuela ^a   Minuz, Pietro ^d   Di Gregorio, Patrizia ^e   Merciaro, Gabriele ^c   Patrono, Carlo ^a,b   Patrignani, Paola ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Ospedale SS Annunziata   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e Università G d'Annunzio ^*

Author keywords

Aspirin; Epoprostenol; Naproxen; Platelets; Thromboxanes

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; NAPROXEN; PROSTACYCLIN; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; THROMBOXANE; THROMBOXANE A2; THROMBOXANE B2;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MONOCYTE; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; PROSTAGLANDIN SYNTHESIS INHIBITION; PROSTAGLANDIN URINE LEVEL; THROMBOCYTE;

6-KETOPROSTAGLANDIN F1 ALPHA; ADULT; ASPIRIN; BLOOD PLATELETS; CARDIOTONIC AGENTS; CROSS-OVER STUDIES; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; ISOENZYMES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MONOCYTES; NAPROXEN; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS I; THROMBOXANE B2;

EID: 12144290072     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000124715.27937.78     Document Type: Article

References (20)

1. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets, I: acetylation of a particulate fraction protein. J Clin Invest. 1975;56:624-632.
2. Lecomte M, Laneuville O, Ji C, et al. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J Biol Chem. 1994;269:13207-13215.
3. Patrono C, Coller B, Dalen JE, et al. Platelet active drugs: the relationships among dose, effectiveness, and side effects. Chest. 2001;119:39S-63S.
4. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
5. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520-1528.
6. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433-442.
7. Van Hecken A, Schwartz JI, Depré M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000;40:1109-1120.
8. Shah AA, Thjodleifsson B, Murray FE, et al. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut. 2001;48:339-346.
9. 2 production in healthy subjects. Thromb Res. 1980;17:317-327.
10. Patrignani P, Panara MR, Greco A, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther. 1994;271:1705-1712.
11. 2 in man. Biochim Biophys Acta. 1989;992:66-70.
12. FitzGerald GA, Brash AR, Falardeau P, et al. Estimated rate of prostacyclin secretion into the circulation of normal man. J Clin Invest. 1981;68:1272-1275.
13. Minuz P, Covi G, Paluani F, et al. Altered excretion of prostaglandin and thromboxane metabolites in pregnancy-induced hypertension. Hypertension. 1988;11:550-556.
14. Mamdani M, Rochon P, Juurlink DN, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med. 2003;163:481-486.
15. Solomon DH, Glynn RJ, Levin R, et al. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med. 2002;162:1099-1104.
16. Watson DJ, Rhodes T, Cai B, et al. Low risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med. 2002;162:1105-1110.
17. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med. 2002;162:1111-1115.
18. Ray WA, Stein M, Hall K, et al. Non-steroidal anti-inflammatory drugs and risk of coronary heart disease: an observational cohort study. Lancet. 2002;359:118-123.
19. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA. 1999;96:272-277.
20. Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther. 1999;289:735-741.